ArticleBMC infectious diseases2025
Analysis of molecular resistance and associated risk factors in tuberculosis.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Recent Advances in Antimicrobial Proteins and Peptides: A Promising Clinical Breakthrough and Patent Landscape.Current protein & peptide science · 2026Review
- Drug Resistance Patterns, Temporal Trends, and Risk Factors Among Elderly Tuberculosis Patients in Anhui, China: A Retrospective Study (2020-2024).Infection and drug resistance · 2026Article
- Global, regional, and national burden of tuberculosis, 1990-2050: a systematic comparative analysis based on retrospective cross-sectional of GBD 2021 and WHO surveillance systems.International journal of surgery (London, England) · 2026Article
- Epidemiology and Molecular Drug-Resistance Patterns of Tuberculosis in Non-Elderly Patients in Luoyang, China, 2019-2023.Infection and drug resistance · 2025Article
- Trends in Drug Resistance and Epidemiological Patterns of Tuberculosis in Elderly Patients in Wenzhou, China (2014-2023).Infection and drug resistance · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundLocal surveillance of molecular resistance to first-line anti-tuberculosis (TB) drugs and fluoroquinolones (FQs) was initiated in 2019, but existing reports remain limited, hindering effective TB prevention and control efforts. This study aims to investigate molecular resistance to first-line anti-TB drugs and FQs, assess risk factors for FQs resistance, and provide insights into the spread of drug-resistant tuberculosis (DR-TB) to inform more effective control and treatment strategies.
methodsSputum samples from 25,150 non-duplicate patients attending 10 designated TB medical institutions across Luoyang City and all county and township areas under its jurisdiction from January 2019 to December 2023 were analyzed via fluorescence real-time PCR to detect Mycobacterium tuberculosis complex (MTBC)-positive strains. Multicolor melting curve analysis (MMCA) was performed on 4,131 non-repetitive MTBC strains to assess their molecular resistance to first-line anti-TB drugs and FQs. Risk factors for FQs resistance and the impact of first-line anti-TB drug resistance on FQs resistance were also assessed.
resultsBetween 2019 and 2023, 4,131 MTBC strains were collected. Resistance to first-line anti-TB drugs was higher in males, retreated patients, individuals younger than 61 years, and those from the main urban area, compared to females, newly diagnosed patients, individuals over 60 years, and residents of county and township areas (59.1% vs. 46.0%, p < 0.001; 85.6% vs. 52.0%, p < 0.001; 60.2% vs. 47.2%, p < 0.001; 47.1% vs. 69.4%, p < 0.001). The overall FQs resistance rate was 7.9% (327 cases). After adjusting for the interaction with first-line anti-TB drugs, the resistance rates to FQs were significantly higher in patients with isoniazid resistance (INH-R), rifampin resistance (RFP-R), and ethambutol resistance (EMB-R), with odds ratios of 2.61 (95% CI 1.77, 3.84, p = 0.002), 4.64 (95% CI 3.13, 6.89, p < 0.001), and 2.86 (95% CI 2.01, 4.07, p < 0.001), respectively, compared to those without resistance.
conclusionsResistance to first-line anti-TB drugs remains high, underscoring the critical role of FQs in TB management. However, the elevated FQs resistance limits their effectiveness against drug-resistant TB. Strengthening DR-TB surveillance and implementing timely, targeted interventions are essential for controlling the spread of DR-TB and achieving the goals of the "End TB Strategy."
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.